ADMA Biologics (ADMA) Financials

ADMA Biologics Inc (ADMA) is a biopharmaceutical company that specializes in the development and commercialization of plasma-derived biologics for the treatment of infectious diseases. The company's primary focus is on the manufacturing and marketing of specialty plasma-derived immunoglobulin products. ADMA's products are used to treat patients with primary immune deficiency disorders and certain other immune deficiencies. The company's key products include BIVIGAM, ASCENIV, and NABI-HB. BIVIGAM is a intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency (PI). ASCENIV is an intravenous immune globulin indicated for the treatment of Primary Humoral Immunodeficiency Disease (PIDD). NABI-HB is a hyperimmune globulin indicated for the treatment of hepatitis B infection.

In terms of financials, ADMA Biologics Inc reported total revenue of $64.8 million for the fiscal year ending December 31, 2020. This represents a significant increase from the previous year's revenue of $43.2 million. The company's gross profit for the same period was $38.4 million, with a gross profit margin of 59%. ADMA's net income from stockholders for the year was $10.2 million, compared to a net loss of $18.9 million in the previous year. The company's EBITDA for 2020 was $11.6 million, while EBIT was $4.8 million. ADMA has a strong balance sheet, with total assets of $155.2 million and total liabilities of $118.2 million as of December 31, 2020.

ADMA Biologics Inc has a healthy cash position, with cash equivalents amounting to $62.1 million as of the end of FY2020. The company also has a positive stockholders' equity of $36.3 million. ADMA's total debt stands at $54.6 million, indicating a relatively low level of debt. In terms of cash flow, the company reported operating cash flow of $4.4 million for the fiscal year, reflecting its ability to generate cash from its core operations. ADMA's investing cash flow was negative $1.5 million, primarily due to investments in property and equipment. The company's financing cash flow was positive $30.2 million, primarily driven by proceeds from the issuance of common stock.

In conclusion, ADMA Biologics Inc is a biopharmaceutical company that has achieved significant growth in revenue and profitability. The company's strong financial performance is supported by its portfolio of specialty plasma-derived immunoglobulin products. ADMA's solid balance sheet, healthy cash position, and positive cash flow demonstrate its financial stability and ability to invest in future growth opportunities. With a focus on the treatment of infectious diseases, ADMA is well-positioned to continue expanding its product portfolio and capturing market share.